Trial Profile
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity With Bortezomib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Natural killer cell therapy (Primary) ; Interleukin-2; Pentostatin
- Indications Adenocarcinoma; Carcinoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Ewing's sarcoma; Glandular and epithelial neoplasms; Haematological malignancies; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 07 Apr 2021 Status changed from recruiting to completed.
- 16 Dec 2020 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
- 16 Dec 2020 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.